Loading
DNA, Viral / RNA / RNA Methylation · Journal article
Epigenetics · September 6, 2026
Early or partial results. Treat as a signal, not a conclusion.
This study reports correlations between serum HBV pgRNA-m6A levels and markers of viral replication and liver function in an unspecified patient cohort, supported by mechanistic evidence from site-specific m6A demethylation in a stable HBV-producing cell line. The findings suggest m6A modification regulates HBV replication but do not yet demonstrate clinical efficacy of m6A-targeted intervention in patients.
Observational serum biomarker study combined with uncontrolled cell line experiments. Patients with chronic HBV infection (setting and eligibility criteria not specified); HepAD38 stable HBV-producing cell line used for mechanistic studies.. Intervention: Site-specific demethylation of pgRNA1907-m6A using TRADES system in cell line; no patient intervention reported.. Compared with: Untreated or wild-type pgRNA in cell line; low viral load patients (HBV DNA ≤ 1.0 × 10^7 IU/mL) in observational comparison..
Serum HBV pgRNA-m6A levels positively correlated with HBV DNA copy number, pgRNA expression, and liver function indicators (all p < 0.05). Both pgRNA-m6A levels and pgRNA expression significantly increased in patients with high viral load (HBV DNA > 1.0 × 10^7 IU/mL). Site-specific demethylation of pgRNA1907-m6A in HepAD38 cells significantly reduced HBV DNA, HBeAg, and HBV pgRNA while inducing IFN-α2 and APOBEC3A.
Cell line data do not address pharmacokinetics, toxicity, or efficacy in vivo.
While the observed associations between pgRNA-m6A and viral replication are mechanistically interesting, the lack of a patient-level intervention study and absence of safety or efficacy data means m6A-targeted therapy cannot yet be recommended for clinical use. Further controlled trials in patients are required.
Mixed mechanistic and observational evidence from cell line and associational human studies without a controlled clinical trial, supporting a hypothesis about m6A modification in HBV but lacking efficacy data in patients.
As stated by the source record.
Quoted from the source exactly as published.
While the observed associations between pgRNA-m6A and viral replication are mechanistically interesting, the lack of a patient-level intervention study and absence of safety or efficacy data means m6A-targeted therapy cannot yet be recommended for clinical use. Further controlled trials in patients are required.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
m6A modification has been shown to play a role in regulating HBV RNA expression. However, it remains unclear whether the m6A levels of HBV pregenomic RNA (pgRNA) are related to HBV replication and liver function. Serum HBV pgRNA-m6A levels were determined by T3 DNA ligase assay. HBV DNA copy numbers and gene expression were detected by TaqMan assay and RT-qPCR, respectively. Liver function was evaluated using clinical laboratory indicators. The TET-off stable HBV-producing cell line HepAD38 and targeted pgRNA demethylation by SunTag system (TRADES) were used for the site-specific m6A editing. Flow cytometry was used to measure the cytokine levels in the supernatant of cell culture. Serum HBV pgRNA-m6A levels were positively correlated with HBV DNA copy number, pgRNA expression and liver function indicators (all p < 0.05). Both pgRNA-m6A levels and pgRNA expression were significantly increased in patients with high virus load (HBV DNA > 1.0 × 107 IU/mL). Site-specific demethylation of pgRNA1907-m6A significantly reduced HBV DNA, hepatitis B e antigen (HBeAg) and HBV pgRNA, while induced levels of interferon alfa 2 (IFN-α2) and apolipoprotein B mRNA editing enzyme catalytic subunit 3A (APOBEC3A). pgRNA-m6A modification of HBV associates with viral replication and liver function indicators. Site-specific m6A demethylation of pgRNA provides novel insight into anti-HBV treatment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.